Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,124 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza Virus Vaccine Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5N1 (Clade 2) Vaccination of Adults and Elderly

NCT00680069
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 99 Years
Enrollment
517 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
8
States / cities
Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

NCT00735475
View directory record Official record
Conditions
Influenza
Interventions
CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
65 Years and older
Enrollment
1,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
13
States / cities
Mountain Home, Arkansas • Boise, Idaho • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

NCT04120194
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu, Fluzone Quadrivalent
Biological
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
2,654 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
19
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Not applicable Interventional

Influenza Vaccine Randomized Educational Trial: Adult

NCT02907645
View directory record Official record
Conditions
Vaccination, Influenza
Interventions
Local educational information, National educational information
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 13, 2026, 10:47 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

NCT06841913
View directory record Official record
Conditions
Smoke Exposure, Influenza
Interventions
LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure)
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 13, 2026, 10:47 PM EDT
Not listed No phase listed Observational

Platelet Immune Responses in Aging and Influenza and Sepsis (INVACS)

NCT03010410
View directory record Official record
Conditions
Sepsis, Influenza
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines

NCT00197288
View directory record Official record
Conditions
Influenza
Interventions
Influenza
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,847 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
15
States / cities
Clearwater, Florida • Evansville, Indiana • Baltimore, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

NCT04025580
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Flucelvax, Fluvirin, Fluzone High Dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 13, 2026, 10:47 PM EDT
Recruiting Phase 3 Interventional

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

NCT06094010
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Weeks to 11 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Harrisburg, Arkansas • Miami, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

NCT01406418
View directory record Official record
Conditions
Influenza
Interventions
CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

NCT00388583
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
17
States / cities
Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Not applicable Interventional

Effectiveness of Influenza Vaccine Reminder Systems

NCT01852656
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease
Interventions
Postcard and IVR Reminder Group, Postcard Only Reminder Group, IVR Only Reminder Group
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
19 Years to 64 Years
Enrollment
12,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 13, 2026, 10:47 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

NCT02927431
View directory record Official record
Conditions
Virus Diseases
Interventions
Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer

NCT01354379
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
NB-1008, Fluzone IN
Biological
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

NCT06436703
View directory record Official record
Conditions
Influenza, Human
Interventions
Influenza ModRNA Vaccine, Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
32
States / cities
Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

NCT03701061
View directory record Official record
Conditions
Influenza A Subtype H5N1 Infection
Interventions
Seasonal Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 13, 2026, 10:47 PM EDT
Completed No phase listed Observational

Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population

NCT04963166
View directory record Official record
Conditions
Influenza Immunity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

NCT00570037
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Not applicable Interventional

Impact of Influenza Vaccination in Pregnancy Video Education

NCT02151201
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccination video education, Hand washing video education
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

NCT00812019
View directory record Official record
Conditions
Influenza
Interventions
Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59, Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years to 40 Years
Enrollment
753 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 13, 2026, 10:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.

NCT04748445
View directory record Official record
Conditions
Healthy
Interventions
SARS-CoV-2/Influenza/RSV RT-PCR
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9,151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 13, 2026, 10:47 PM EDT
Completed No phase listed Observational Results available

Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza

NCT01769430
View directory record Official record
Conditions
Influenza Virus Infection Transmission in Humans
Interventions
Observational Study of influenza aerosol shedding -- No Intervention
Other
Lead sponsor
University of Maryland, College Park
Other
Eligibility
10 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 13, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

NCT03058692
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Multimeric-001 Vaccine, Placebo, Quadrivalent Recombinant Seasonal Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 13, 2026, 10:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Fluarix/ FluLaval/ Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry

NCT02148211
View directory record Official record
Conditions
Influenza
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Female only
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 13, 2026, 10:47 PM EDT